Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $9.89B | $9.68B | +2.22% |
Cost of Revenue | $2.4B | $2.31B | +4.06% |
Net Income | $1.29B | $1.63B | -20.79% |
EPS (Basic) | $8.83 | $11.21 | -21.23% |
EPS (Diluted) | $8.79 | $11.18 | -21.38% |
SG&A Expense | $2.43B | $2.4B | +1.24% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $29.44B | $28.05B | +4.96% |
Current Assets | $8.97B | $7.46B | +20.35% |
Total Liabilities | $11.18B | $11.33B | -1.33% |
Current Liabilities | $3.35B | $5.53B | -39.42% |
Long-Term Debt | $6.29B | $4.55B | +38.26% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $2.2B | $2.88B | -23.33% |
Investing Cash Flow | $-1.37B | $-799.2M | -71.56% |
Financing Cash Flow | $-301.9M | $-683.5M | +55.83% |
D&A | $779.9M | $673.2M | +15.85% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 13.1% | — | — |
ROA | 4.4% | — | — |
Current Ratio | $2.679 | — | — |
BIIB's 2025 fiscal year shows modest revenue growth but significant declines in net income and EPS, highlighting cost pressures and increased long-term debt.
BIIB achieved a 2.2% increase in revenue, driven by strong sales in key therapeutic areas.
Source: Source: 10-K Income Statement, p.1
Cost of revenue increased by 4.1%, impacting profitability despite revenue growth.
Source: Source: 10-K Income Statement, p.1
Long-term debt rose by 38.3%, indicating increased leverage to support business operations.
Source: Source: 10-K Balance Sheet, p.1
Net income decreased by 20.8%, which could affect future investment and dividend capabilities.
Source: Source: 10-K Income Statement, p.1
Unlock 2 more detailed risk analysis
Upgrade to unlockOther companies in Biotechnology